EXEL
XNASExelixis Inc
Basic Materials · Biological Products, (No Diagnostic Substances)
$43.98
+0.32 (+0.73%)
15-min delayed
Drag to pan · Scroll to zoom · Hover for OHLC
Snapshot
Loading metrics…
About Exelixis Inc
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Employees
1,077
Country
US
IPO Date
2000-04-11
Recent News
Assessing Exelixis (EXEL) Valuation After Mixed Share Performance And CABOMETYX Growth Narrative
Yahoo · 2d ago
Exelixis Inc (NASDAQ:EXEL) Passes the Caviar Cruise Quality Screen with Zero Debt and 54% ROIC
ChartMill · 5d ago
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Yahoo · 6d ago
Pancreatic Neuroendocrine Tumors Market Research Report 2025-2035, Competitive Analysis of Key Players - Novartis, Pfizer, Exelixis, Merck, Ipsen Pharma, and Takeda Pharma
Yahoo · 6d ago
Recursion Pharmaceuticals May Be Losing Ground To Its Peers
SeekingAlpha · 6d ago
Analyst Ratings
Loading…
Financials
Loading SEC filings…
Insider Activity
Loading filings…
Related Stocks
Loading peers…
Data is 15-minute delayed, for informational purposes only. Not investment advice. Prices via Massive.com consolidated feed. Fundamentals via FinancialModelingPrep. News via Finnhub.